Cognition Therapeutics Stock Book Value Per Share
| CGTX Stock | USD 0.44 0.02 4.35% |
Cognition Therapeutics fundamentals help investors to digest information that contributes to Cognition Therapeutics' financial success or failures. It also enables traders to predict the movement of Cognition Stock. The fundamental analysis module provides a way to measure Cognition Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cognition Therapeutics stock.
Cognition |
Cognition Therapeutics Company Book Value Per Share Analysis
Cognition Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Cognition Therapeutics Book Value Per Share | 0.76 X |
Most of Cognition Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cognition Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Cognition Therapeutics is about 0.761 times. This is 144.76% lower than that of the Biotechnology sector and 100.31% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.96% higher than that of the company.
Cognition Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cognition Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cognition Therapeutics could also be used in its relative valuation, which is a method of valuing Cognition Therapeutics by comparing valuation metrics of similar companies.Cognition Therapeutics is currently under evaluation in book value per share category among its peers.
Cognition Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.94 | ||||
| Current Valuation | (3.15 M) | ||||
| Shares Outstanding | 41.55 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 24.53 % | ||||
| Number Of Shares Shorted | 815.7 K | ||||
| Price To Book | 1.26 X | ||||
| EBITDA | (25.51 M) | ||||
| Net Income | (25.79 M) | ||||
| Cash And Equivalents | 46.61 M | ||||
| Cash Per Share | 1.94 X | ||||
| Total Debt | 1.24 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 0.76 X | ||||
| Cash Flow From Operations | (16.02 M) | ||||
| Short Ratio | 1.07 X | ||||
| Earnings Per Share | (0.96) X | ||||
| Target Price | 6.2 | ||||
| Number Of Employees | 25 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 18.28 M | ||||
| Total Asset | 35.16 M | ||||
| Retained Earnings | (141.19 M) | ||||
| Working Capital | 24.05 M | ||||
| Net Asset | 35.16 M |
About Cognition Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cognition Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cognition Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cognition Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.